What happened
Chai Discovery, an AI drug development startup originating from OpenAI's offices, established a partnership with Eli Lilly. This collaboration integrates Chai Discovery's AI capabilities into Eli Lilly's drug development processes. Concurrently, the startup secured financial backing from influential Silicon Valley venture capitalists, expanding its operational resources and external dependencies for future development.
Why it matters
This partnership introduces a new external dependency for Eli Lilly's drug development pipeline, requiring increased due diligence from procurement and R&D operations regarding AI model provenance, data security, and intellectual property rights associated with Chai Discovery's contributions. The involvement of influential VCs also raises the oversight burden for compliance and legal teams concerning potential future acquisition or strategic shifts impacting the collaboration.
